Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The study attempts to evaluate a histamine analog long used for the treatment of Meniere's
disease, betahistine, that shows promise in reversing the antihistaminergic effects thought
to be involved in antipsychotic induced weight gain.
Hypothesis to be tested:
A. Patients who have gained a developmentally inappropriate amount of weight on
antipsychotics (AP) will see their weight and BMI decrease with betahistine augmentation as
compared to placebo augmentation.
B. Betahistine augmentation in AP treated patients will increase levels of satiety in a
standardized meal situation and decrease caloric intake as compared to placebo augmentation.
C. Metabolic effects of betahistine augmentation in AP treated patients will be reflected in
differences in waist circumference, hip circumference and waist hip ratios D. Betahistine
augmentation in this population will lead to decrease in fasting glucose-lipid lab values
related to the development of metabolic syndrome as compared to placebo augmentation